Review





Similar Products

small heterodimer partner shp antibody  (Bioss)
94
Bioss small heterodimer partner shp antibody
Small Heterodimer Partner Shp Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+heterodimer+partner/pm40056637-70-0-8?v=Bioss
Average 94 stars, based on 1 article reviews
small heterodimer partner shp antibody - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
small heterodimer partner shp  (OriGene)
94
OriGene small heterodimer partner shp
Small Heterodimer Partner Shp, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+heterodimer+partner/pm41605656-81-60-67?v=OriGene
Average 94 stars, based on 1 article reviews
small heterodimer partner shp - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
shp small heterodimer partner t2dm type 2 diabetes mellitus tgr5 takeda g protein coupled receptor 5  (Takeda)
86
Takeda shp small heterodimer partner t2dm type 2 diabetes mellitus tgr5 takeda g protein coupled receptor 5
Mechanisms linking GLP-1R agonists to gallstone formation. GLP-1RAs suppress CCK secretion, reducing gallbladder contractility and promoting bile retention. They also alter <t>TGR5</t> signaling, decreasing cAMP-mediated gallbladder relaxation and bile acid-induced GLP-1 secretion. In addition, GLP-1RAs disrupt FXR signaling by reducing FGF19 production, leading to dysregulation of bile acid synthesis and transport through pathways involving cholesterol 7α-hydroxylase (CYP7A1), sterol 12α-hydroxylase (CYP12), and the BSEP. At the neural level, GLP-1RAs activate GLP-1R in the NTS and AP, altering vagal nerve signaling and causing asynchronous contractions of the gallbladder. These combined alterations result in biliary stasis, characterized by prolonged retention of bile and supersaturation with cholesterol, which favors gallstone formation. AP, area postrema; BSEP, bile salt export pump; cAMP, cyclic adenosine monophosphate; CCK, cholecystokinin; FGF19, fibroblast growth factor 19; FXR, farnesoid X receptor; GLP-1RAs, glucagon-like peptide-1 receptor agonists; NTS, nucleus tractus solitaries; TGR5, Takeda G-protein-coupled receptor 5.
Shp Small Heterodimer Partner T2dm Type 2 Diabetes Mellitus Tgr5 Takeda G Protein Coupled Receptor 5, supplied by Takeda, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+heterodimer+partner/pmc12739101-156-80-90?v=Takeda
Average 86 stars, based on 1 article reviews
shp small heterodimer partner t2dm type 2 diabetes mellitus tgr5 takeda g protein coupled receptor 5 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
anti-small heterodimer partner (shp, cat# a1836, lot# 5500010184) antibody  (ABclonal Biotechnology)
90
ABclonal Biotechnology anti-small heterodimer partner (shp, cat# a1836, lot# 5500010184) antibody
Mechanisms linking GLP-1R agonists to gallstone formation. GLP-1RAs suppress CCK secretion, reducing gallbladder contractility and promoting bile retention. They also alter <t>TGR5</t> signaling, decreasing cAMP-mediated gallbladder relaxation and bile acid-induced GLP-1 secretion. In addition, GLP-1RAs disrupt FXR signaling by reducing FGF19 production, leading to dysregulation of bile acid synthesis and transport through pathways involving cholesterol 7α-hydroxylase (CYP7A1), sterol 12α-hydroxylase (CYP12), and the BSEP. At the neural level, GLP-1RAs activate GLP-1R in the NTS and AP, altering vagal nerve signaling and causing asynchronous contractions of the gallbladder. These combined alterations result in biliary stasis, characterized by prolonged retention of bile and supersaturation with cholesterol, which favors gallstone formation. AP, area postrema; BSEP, bile salt export pump; cAMP, cyclic adenosine monophosphate; CCK, cholecystokinin; FGF19, fibroblast growth factor 19; FXR, farnesoid X receptor; GLP-1RAs, glucagon-like peptide-1 receptor agonists; NTS, nucleus tractus solitaries; TGR5, Takeda G-protein-coupled receptor 5.
Anti Small Heterodimer Partner (Shp, Cat# A1836, Lot# 5500010184) Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+heterodimer+partner/pm40222688-89-1-14?v=ABclonal+Biotechnology
Average 90 stars, based on 1 article reviews
anti-small heterodimer partner (shp, cat# a1836, lot# 5500010184) antibody - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
anti-small heterodimer partner (shp)  (ABclonal Biotechnology)
90
ABclonal Biotechnology anti-small heterodimer partner (shp)
Mechanisms linking GLP-1R agonists to gallstone formation. GLP-1RAs suppress CCK secretion, reducing gallbladder contractility and promoting bile retention. They also alter <t>TGR5</t> signaling, decreasing cAMP-mediated gallbladder relaxation and bile acid-induced GLP-1 secretion. In addition, GLP-1RAs disrupt FXR signaling by reducing FGF19 production, leading to dysregulation of bile acid synthesis and transport through pathways involving cholesterol 7α-hydroxylase (CYP7A1), sterol 12α-hydroxylase (CYP12), and the BSEP. At the neural level, GLP-1RAs activate GLP-1R in the NTS and AP, altering vagal nerve signaling and causing asynchronous contractions of the gallbladder. These combined alterations result in biliary stasis, characterized by prolonged retention of bile and supersaturation with cholesterol, which favors gallstone formation. AP, area postrema; BSEP, bile salt export pump; cAMP, cyclic adenosine monophosphate; CCK, cholecystokinin; FGF19, fibroblast growth factor 19; FXR, farnesoid X receptor; GLP-1RAs, glucagon-like peptide-1 receptor agonists; NTS, nucleus tractus solitaries; TGR5, Takeda G-protein-coupled receptor 5.
Anti Small Heterodimer Partner (Shp), supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+heterodimer+partner/pmc11889867-84-9-13?v=ABclonal+Biotechnology
Average 90 stars, based on 1 article reviews
anti-small heterodimer partner (shp) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
small heterodimer partner shp  (ImmunoWay Biotechnology Company)
90
ImmunoWay Biotechnology Company small heterodimer partner shp
Mechanisms linking GLP-1R agonists to gallstone formation. GLP-1RAs suppress CCK secretion, reducing gallbladder contractility and promoting bile retention. They also alter <t>TGR5</t> signaling, decreasing cAMP-mediated gallbladder relaxation and bile acid-induced GLP-1 secretion. In addition, GLP-1RAs disrupt FXR signaling by reducing FGF19 production, leading to dysregulation of bile acid synthesis and transport through pathways involving cholesterol 7α-hydroxylase (CYP7A1), sterol 12α-hydroxylase (CYP12), and the BSEP. At the neural level, GLP-1RAs activate GLP-1R in the NTS and AP, altering vagal nerve signaling and causing asynchronous contractions of the gallbladder. These combined alterations result in biliary stasis, characterized by prolonged retention of bile and supersaturation with cholesterol, which favors gallstone formation. AP, area postrema; BSEP, bile salt export pump; cAMP, cyclic adenosine monophosphate; CCK, cholecystokinin; FGF19, fibroblast growth factor 19; FXR, farnesoid X receptor; GLP-1RAs, glucagon-like peptide-1 receptor agonists; NTS, nucleus tractus solitaries; TGR5, Takeda G-protein-coupled receptor 5.
Small Heterodimer Partner Shp, supplied by ImmunoWay Biotechnology Company, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+heterodimer+partner/pm39547094-97-82-87?v=ImmunoWay+Biotechnology+Company
Average 90 stars, based on 1 article reviews
small heterodimer partner shp - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
antibodies for small heterodimer partner (shp) (#df3873)  (Affinity Biosciences)
90
Affinity Biosciences antibodies for small heterodimer partner (shp) (#df3873)
Mechanisms linking GLP-1R agonists to gallstone formation. GLP-1RAs suppress CCK secretion, reducing gallbladder contractility and promoting bile retention. They also alter <t>TGR5</t> signaling, decreasing cAMP-mediated gallbladder relaxation and bile acid-induced GLP-1 secretion. In addition, GLP-1RAs disrupt FXR signaling by reducing FGF19 production, leading to dysregulation of bile acid synthesis and transport through pathways involving cholesterol 7α-hydroxylase (CYP7A1), sterol 12α-hydroxylase (CYP12), and the BSEP. At the neural level, GLP-1RAs activate GLP-1R in the NTS and AP, altering vagal nerve signaling and causing asynchronous contractions of the gallbladder. These combined alterations result in biliary stasis, characterized by prolonged retention of bile and supersaturation with cholesterol, which favors gallstone formation. AP, area postrema; BSEP, bile salt export pump; cAMP, cyclic adenosine monophosphate; CCK, cholecystokinin; FGF19, fibroblast growth factor 19; FXR, farnesoid X receptor; GLP-1RAs, glucagon-like peptide-1 receptor agonists; NTS, nucleus tractus solitaries; TGR5, Takeda G-protein-coupled receptor 5.
Antibodies For Small Heterodimer Partner (Shp) (#Df3873), supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+heterodimer+partner/pm39368342-72-29-42?v=Affinity+Biosciences
Average 90 stars, based on 1 article reviews
antibodies for small heterodimer partner (shp) (#df3873) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
antibodies small heterodimer partner (shp) df3873  (Affinity Biosciences)
90
Affinity Biosciences antibodies small heterodimer partner (shp) df3873
Mechanisms linking GLP-1R agonists to gallstone formation. GLP-1RAs suppress CCK secretion, reducing gallbladder contractility and promoting bile retention. They also alter <t>TGR5</t> signaling, decreasing cAMP-mediated gallbladder relaxation and bile acid-induced GLP-1 secretion. In addition, GLP-1RAs disrupt FXR signaling by reducing FGF19 production, leading to dysregulation of bile acid synthesis and transport through pathways involving cholesterol 7α-hydroxylase (CYP7A1), sterol 12α-hydroxylase (CYP12), and the BSEP. At the neural level, GLP-1RAs activate GLP-1R in the NTS and AP, altering vagal nerve signaling and causing asynchronous contractions of the gallbladder. These combined alterations result in biliary stasis, characterized by prolonged retention of bile and supersaturation with cholesterol, which favors gallstone formation. AP, area postrema; BSEP, bile salt export pump; cAMP, cyclic adenosine monophosphate; CCK, cholecystokinin; FGF19, fibroblast growth factor 19; FXR, farnesoid X receptor; GLP-1RAs, glucagon-like peptide-1 receptor agonists; NTS, nucleus tractus solitaries; TGR5, Takeda G-protein-coupled receptor 5.
Antibodies Small Heterodimer Partner (Shp) Df3873, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+heterodimer+partner/pm39368342-72-34-42?v=Affinity+Biosciences
Average 90 stars, based on 1 article reviews
antibodies small heterodimer partner (shp) df3873 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
small heterodimer partner  (Santa Cruz Biotechnology)
95
Santa Cruz Biotechnology small heterodimer partner
Mechanisms linking GLP-1R agonists to gallstone formation. GLP-1RAs suppress CCK secretion, reducing gallbladder contractility and promoting bile retention. They also alter <t>TGR5</t> signaling, decreasing cAMP-mediated gallbladder relaxation and bile acid-induced GLP-1 secretion. In addition, GLP-1RAs disrupt FXR signaling by reducing FGF19 production, leading to dysregulation of bile acid synthesis and transport through pathways involving cholesterol 7α-hydroxylase (CYP7A1), sterol 12α-hydroxylase (CYP12), and the BSEP. At the neural level, GLP-1RAs activate GLP-1R in the NTS and AP, altering vagal nerve signaling and causing asynchronous contractions of the gallbladder. These combined alterations result in biliary stasis, characterized by prolonged retention of bile and supersaturation with cholesterol, which favors gallstone formation. AP, area postrema; BSEP, bile salt export pump; cAMP, cyclic adenosine monophosphate; CCK, cholecystokinin; FGF19, fibroblast growth factor 19; FXR, farnesoid X receptor; GLP-1RAs, glucagon-like peptide-1 receptor agonists; NTS, nucleus tractus solitaries; TGR5, Takeda G-protein-coupled receptor 5.
Small Heterodimer Partner, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+heterodimer+partner/pm38863408-59-20-34?v=Santa+Cruz+Biotechnology
Average 95 stars, based on 1 article reviews
small heterodimer partner - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

Image Search Results


Mechanisms linking GLP-1R agonists to gallstone formation. GLP-1RAs suppress CCK secretion, reducing gallbladder contractility and promoting bile retention. They also alter TGR5 signaling, decreasing cAMP-mediated gallbladder relaxation and bile acid-induced GLP-1 secretion. In addition, GLP-1RAs disrupt FXR signaling by reducing FGF19 production, leading to dysregulation of bile acid synthesis and transport through pathways involving cholesterol 7α-hydroxylase (CYP7A1), sterol 12α-hydroxylase (CYP12), and the BSEP. At the neural level, GLP-1RAs activate GLP-1R in the NTS and AP, altering vagal nerve signaling and causing asynchronous contractions of the gallbladder. These combined alterations result in biliary stasis, characterized by prolonged retention of bile and supersaturation with cholesterol, which favors gallstone formation. AP, area postrema; BSEP, bile salt export pump; cAMP, cyclic adenosine monophosphate; CCK, cholecystokinin; FGF19, fibroblast growth factor 19; FXR, farnesoid X receptor; GLP-1RAs, glucagon-like peptide-1 receptor agonists; NTS, nucleus tractus solitaries; TGR5, Takeda G-protein-coupled receptor 5.

Journal: Therapeutic Advances in Endocrinology and Metabolism

Article Title: GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications

doi: 10.1177/20420188251406456

Figure Lengend Snippet: Mechanisms linking GLP-1R agonists to gallstone formation. GLP-1RAs suppress CCK secretion, reducing gallbladder contractility and promoting bile retention. They also alter TGR5 signaling, decreasing cAMP-mediated gallbladder relaxation and bile acid-induced GLP-1 secretion. In addition, GLP-1RAs disrupt FXR signaling by reducing FGF19 production, leading to dysregulation of bile acid synthesis and transport through pathways involving cholesterol 7α-hydroxylase (CYP7A1), sterol 12α-hydroxylase (CYP12), and the BSEP. At the neural level, GLP-1RAs activate GLP-1R in the NTS and AP, altering vagal nerve signaling and causing asynchronous contractions of the gallbladder. These combined alterations result in biliary stasis, characterized by prolonged retention of bile and supersaturation with cholesterol, which favors gallstone formation. AP, area postrema; BSEP, bile salt export pump; cAMP, cyclic adenosine monophosphate; CCK, cholecystokinin; FGF19, fibroblast growth factor 19; FXR, farnesoid X receptor; GLP-1RAs, glucagon-like peptide-1 receptor agonists; NTS, nucleus tractus solitaries; TGR5, Takeda G-protein-coupled receptor 5.

Article Snippet: ATP adenosine triphosphate BSEP/ABCB11 bile salt export pump Ca 2+ calcium ions cAMP cyclic adenosine monophosphate CCK cholecystokinin CYP7A1 cholesterol 7α-hydroxylase CYP8B1 sterol 12α-hydroxylase Epac2 exchange protein activated by cAMP-2 FGF19 fibroblast growth factor 19 FGFR4 fibroblast growth factor receptor 4 FXR farnesoid X receptor GLP-1 glucagon-like peptide-1 GLP-1R GLP-1 receptor GLP-1RAs glucagon-like peptide-1 receptor agonists HNF4α hepatocyte nuclear factor 4α IR insulin resistance MASLD metabolically associated steatotic liver disease NTS nucleus of the solitary tract PKA protein kinase A SHP small heterodimer partner T2DM type 2 diabetes mellitus TGR5 Takeda G-protein-coupled receptor 5

Techniques: